Eribulin—A review of preclinical and clinical studies

Slides:

Advertisements

Similar presentations

Auditory nerve disease and auditory neuropathy spectrum disorders Kimitaka Kaga Auris Nasus Larynx Volume 43, Issue 1, Pages (February 2016) DOI:

Advertisements

Perimenopausal migraine in women with vasomotor symptoms E. Anne MacGregor Maturitas Volume 71, Issue 1, Pages (January 2012) DOI: /j.maturitas

The most efficient STR loci in forensic genetics in population of central Poland R. Jacewicz, M. Jedrzejczyk, J. Berent Forensic Science International:

The Survival Kit: Software to analyze survival data including possibly correlated random effects G. Mészáros, J. Sölkner, V. Ducrocq Computer Methods and.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature María Teresa Martínez, José Alejandro Pérez-Fidalgo, Paloma Martín-Martorell,

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Towards diagnostic conversational profiles of patients presenting with dementia or functional memory disorders to memory clinics Christopher Elsey, Paul.

Combined estrogen–progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats L.A. Olatunji,

Influence of maternal nicotine exposure during gestation and lactation on lactate dehydrogenase isoenzyme profile and transcript levels in developing neonatal.

Gastric cancer Critical Reviews in Oncology / Hematology

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Cloé Brami, Ting Bao, Gary Deng Critical.

Novel targets in gastric and esophageal cancer

Critical Reviews in Oncology / Hematology

Nicoletta Colombo, Martin Gore

The importance of Guthrie cards and other medical samples for the direct matching of disaster victims using DNA profiling D. Hartman, L. Benton, L. Morenos,

Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? Séverine Guiu, Anita Wolfer, William Jacot, Pierre.

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force Silvio Monfardini,

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery David Palma, Otto.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

The case for wider use of recombinant factor VIII concentrates

Critical Reviews in Oncology / Hematology

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer Sandro Pignata, Enrico.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne.

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

The see-saw of Keap1-Nrf2 pathway in cancer

Amy M. Lin, Charles J. Ryan, Eric J. Small

Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment Diego Marquez-Medina, Sanjay Popat

Genistein: Its role in metabolic diseases and cancer

Jonathan P. Evans, Paul A. Sutton, Boleslaw K. Winiarski, Stephen W

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

Iron overload and chelation therapy in myelodysplastic syndromes

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

Volume 64, Pages e1-e3 (January 2017)

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Critical Reviews in Oncology / Hematology

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment Judith Maresch, Sebastian F. Schoppmann,

P. Therasse, S. Carbonnelle, J. Bogaerts

Olfa Baroudi, Amel Benammar-elgaaied

Clinically useful prognostic factors in acute myeloid leukemia

Erkan Söğüt, Hasan Kadı, Metin Karayakalı, Cuma Mertoğlu

A randomised clinical trial of routine versus selective CT imaging in acute abdomen: Impact of patient age on treatment costs and hospital resource use

Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward

Critical Reviews in Oncology / Hematology

Primary renal carcinoid: Treatment and prognosis

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello Critical.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Miguel.

Gerhard J. Molderings Critical Reviews in Oncology / Hematology

William L. Lanier, MD Mayo Clinic Proceedings

Pralidoxime for organophosphate poisoning

Preoperative position splint versus skin traction in patients with hip fracture: An experimental study Betul Tosun, Ozlem Aslan, Servet Tunay International.

Oxidative stress in autism

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Catherine J. Hunter, Isabelle G. De Plaen Pathophysiology

Antibiotic De-Escalation

David A. Clark, Upender K. Munshi Pathophysiology

Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression Corline Brouwers, Stefan.

What is type 2 diabetes? Medicine

N. Scaramozzino, P. Terrenoire, L. Baron

Increasing incidence of brain tumours in sparsely populated areas

Interstitial muscle concentrations of rocuronium under steady-state conditions in anaesthetized dogs: actual versus predicted values Ezzine S. , Varin.

Effects of the most common methods for the enhancement of latent fingerprints on DNA extraction from forensic samples S. Gino, M. Omedei Forensic Science.

T.G. Hansen, K.F. Ilett, S.I. Lim, C. Reid, L.P. Hackett, R. Bergesio

Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration Simon M.J.G. , Veering.

Presentation transcript:

Eribulin—A review of preclinical and clinical studies Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel Critical Reviews in Oncology / Hematology Volume 81, Issue 2, Pages 163-184 (February 2012) DOI: 10.1016/j.critrevonc.2011.03.002 Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Chemical structure of halichondrin B. Critical Reviews in Oncology / Hematology 2012 81, 163-184DOI: (10.1016/j.critrevonc.2011.03.002) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Chemical structure of eribulin mesylate. Critical Reviews in Oncology / Hematology 2012 81, 163-184DOI: (10.1016/j.critrevonc.2011.03.002) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 Mechanism of action of eribulin (courtesy EISAI). Critical Reviews in Oncology / Hematology 2012 81, 163-184DOI: (10.1016/j.critrevonc.2011.03.002) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 4 Plasma Cmax versus dose following a 1-h infusion of eribulin on day 1. (B) Plasma area under the concentration–time curve (AUC0-8) versus dose following a 1-h infusion of eribulin on day 1. (C) Plasma concentration versus time profile for the 1.0mg/m2 treatment group (n=9). From: Ref. [10]. Critical Reviews in Oncology / Hematology 2012 81, 163-184DOI: (10.1016/j.critrevonc.2011.03.002) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 5 Eribulin related adverse events of interest or ≥10% incidence as seen in 394 patients with MBC [55,56]. Critical Reviews in Oncology / Hematology 2012 81, 163-184DOI: (10.1016/j.critrevonc.2011.03.002) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions